<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19194557</article-id><article-id pub-id-type="pmc">2633177</article-id><article-id pub-id-type="doi">10.3346/jkms.2009.24.S1.S22</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Mildly Elevated Serum Bilirubin Level is Negatively Associated with the Incidence of End Stage Renal Disease in Patients with IgA Nephropathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chin</surname><given-names>Ho Jun</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="aff" rid="A3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Hyun Jin</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Tae Woo</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Na</surname><given-names>Ki Young</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="aff" rid="A3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Oh</surname><given-names>Kook Hwan</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="aff" rid="A3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Joo</surname><given-names>Kwon Wook</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="aff" rid="A3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Hyung Jin</given-names></name><xref ref-type="aff" rid="A4">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Yon-Su</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="aff" rid="A3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Curie</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="aff" rid="A3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Jin Suk</given-names></name><xref ref-type="aff" rid="A3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Suhnggwon</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="aff" rid="A3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Jeon</surname><given-names>En Sil</given-names></name><xref ref-type="aff" rid="A5">&#x02225;</xref></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Dong Chan</given-names></name><xref ref-type="aff" rid="A6">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Yong-Lim</given-names></name><xref ref-type="aff" rid="A7">**</xref></contrib><contrib contrib-type="author"><name><surname>Park</surname><given-names>Sun-Hee</given-names></name><xref ref-type="aff" rid="A7">**</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Chan-Duck</given-names></name><xref ref-type="aff" rid="A7">**</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Young Rim</given-names></name><xref ref-type="aff" rid="A8">&#x02020;&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Seong Gyun</given-names></name><xref ref-type="aff" rid="A8">&#x02020;&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Yoon Goo</given-names></name><xref ref-type="aff" rid="A9">&#x02021;&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jung Eun</given-names></name><xref ref-type="aff" rid="A9">&#x02021;&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Oh</surname><given-names>Yoon Kyu</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="aff" rid="A10">&#x000a7;&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Chun Soo</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="aff" rid="A10">&#x000a7;&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Sang Koo</given-names></name><xref ref-type="aff" rid="A11">&#x02225;&#x02225;</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chae</surname><given-names>Dong-Wan</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="aff" rid="A3">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Won Yong</given-names></name><xref ref-type="aff" rid="A12">&#x000b6;&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hyoung Kyu</given-names></name><xref ref-type="aff" rid="A12">&#x000b6;&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Jo</surname><given-names>Sang-Kyung</given-names></name><xref ref-type="aff" rid="A12">&#x000b6;&#x000b6;</xref></contrib><contrib contrib-type="author"><collab>The Progressive REnal disease and Medical Informatics and gEnomics Research (PREMIER) members</collab><xref ref-type="author-notes" rid="FN1">1</xref></contrib></contrib-group><aff id="A1"><label>*</label>Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</aff><aff id="A2"><label>&#x02020;</label>Renal Research Institute, Seoul National University College of Medicine, Seoul, Korea.</aff><aff id="A3"><label>&#x02021;</label>Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.</aff><aff id="A4"><label>&#x000a7;</label>Clinical Research Institute, Seoul National University Hospital, Seoul, Korea.</aff><aff id="A5"><label>&#x02225;</label>Biotechnology Center, Pohang University of Science and Technology, Pohang, Korea.</aff><aff id="A6"><label>&#x000b6;</label>Department of Internal Medicine, Catholic University Medical College, Seoul, Korea.</aff><aff id="A7"><label>**</label>Department of Internal Medicine, Kyungpook National University, School of Medicine, Daegu, Korea.</aff><aff id="A8"><label>&#x02020;&#x02020;</label>Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea.</aff><aff id="A9"><label>&#x02021;&#x02021;</label>Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea.</aff><aff id="A10"><label>&#x000a7;&#x000a7;</label>Department of Internal Medicine, Seoul National University College of Medicine, Boramae Medical Center, Seoul, Korea.</aff><aff id="A11"><label>&#x02225;&#x02225;</label>Department of Internal Medicine, Ulsan University College of Medicine, Asan Medical Center, Seoul, Korea.</aff><aff id="A12"><label>&#x000b6;&#x000b6;</label>Department of Internal Medicine and the Institute of Renal Disease, Korea University College of Medicine, Seoul, Korea.</aff><author-notes><corresp>Address for correspondence: Dong-Wan Chae, M.D. Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam 463-707, Korea. Tel: +82.31-787-7025, Fax: +82.31-787-4052, <email>mednep@snubh.org</email></corresp><fn id="FN1" fn-type="other"><p><sup>1</sup>Members are listed in Appendix.</p></fn></author-notes><pub-date pub-type="ppub"><month>1</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>28</day><month>1</month><year>2009</year></pub-date><volume>24</volume><issue>Suppl 1</issue><fpage>S22</fpage><lpage>S29</lpage><history><date date-type="received"><day>02</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>17</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 The Korean Academy of Medical Sciences</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Oxidative stress plays various roles in the development and progression of IgA nephropathy, while bilirubin is known as a potent antioxidant. We therefore hypothesized that serum bilirubin would be associated with renal prognosis in IgA nephropathy. The study subjects comprised 1,458 adult patients with primary IgA nephropathy in Korea. We grouped patients according to the following quartile levels of bilirubin: &#x0003c;0.4 mg/dL (Q1), 0.4-0.5 mg/dL (Q2), 0.6-0.7 mg/dL (Q3), and &#x0003e;0.8 mg/dL (Q4). The outcome data were obtained from the Korean Registry of end-stage renal disease (ESRD). Eighty patients (5.5%) contracted ESRD during a mean follow-up period of 44.9 months. The ESRD incidences were 10.7% in Q1, 8.2% in Q2, 2.8% in Q3, and 2.8% in Q4 (<italic>p</italic>&#x0003c;0.001). The relative risk of ESRD compared to that in Q1 was 0.307 (95% confidence interval [CI], 0.126-0.751) in Q3 and 0.315 (95% CI, 0.130-0.765) in Q4. The differences of ESRD incidence were greater in subgroups of males and of patients aged 35 yr or more, with serum albumin 4.0 g/dL or more, with normotension, with eGFR 60 mL/min/1.73 m<sup>2</sup> or more, and with proteinuria less then 3+ by dipstick test. In conclusion, higher bilirubin level was negatively associated with ESRD incidence in IgA nephropathy.</p></abstract><kwd-group><kwd>Bilirubin</kwd><kwd>Glomerulonephritis, IGA</kwd><kwd>Kidney Failure, Chronic</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>As the most common glomerulonephritis worldwide, IgA nephropathy has the potential for slowly progressive chronic renal impairment, leading to end-stage renal disease (ESRD) (<xref ref-type="bibr" rid="B1">1</xref>). Although many studies have identified the features related to poor prognosis, no single or combination of prognostic factors has been demonstrated to account for the overall risk for ESRD in IgA nephropathy (<xref ref-type="bibr" rid="B2">2</xref>). Until now, no treatment has been shown to modify the mesangial deposition of IgA and the available treatment options are directed at downstream immune reaction to lead on to renal scaring (<xref ref-type="bibr" rid="B2">2</xref>).</p><p>Although the glomerular injury in IgA nephropathy is usually provoked by IgA-induced mesangial cell activation and complement activation (<xref ref-type="bibr" rid="B2">2</xref>), increased oxidative stress was reported to play a role in the development and progression of IgA nephropathy (<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B6">6</xref>). The oxidative stress detected in the reduced glutathione and hemoglobin oxidation on peripheral red blood cells (RBCs) and lipid peroxidation in RBCs and plasma was increased in patients with IgA nephropathy compared to normal controls (<xref ref-type="bibr" rid="B6">6</xref>), as was the immunohistochemistry for intrarenal 4-hidroxy-2-nonenal as the product of lipid peroxidation (<xref ref-type="bibr" rid="B4">4</xref>). The renal infiltration of polymorphonuclear leukocyte which has a high potential for the production of reactive oxygen species (ROS) increased in patients with IgA nephropathy (<xref ref-type="bibr" rid="B5">5</xref>). Advanced oxidation protein products increased in IgA nephropathy compared with that in stable IgA nephropathy and was an independent risk factor to the renal outcome of IgA nephropathy (<xref ref-type="bibr" rid="B3">3</xref>). Intrarenal immunore-activity of heme oxygenase-1 (HO-1), which is the inducible HO isoform that metabolizes heme to carbon monoxide, iron, and bilirubin converted from biliverdin, also increased in IgA nephropathy compared to that in controls (<xref ref-type="bibr" rid="B4">4</xref>).</p><p>Bilirubin is not merely an end product of heme degradation but a potent antioxidant (<xref ref-type="bibr" rid="B7">7</xref>) which is usually mediated by inhibition of NADPH oxidase (<xref ref-type="bibr" rid="B8">8</xref>), a key source of oxidants in phagocytic and non-phagocytic cells, and of protein kinase C activity (<xref ref-type="bibr" rid="B9">9</xref>). Several studies have been published showing the relation between serum bilirubin and oxidative stress-mediated diseases, including coronary artery disease (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>), angiotensin II-mediated hypertension (<xref ref-type="bibr" rid="B12">12</xref>), and renal ischemia-reperfusion injury in vivo (<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>).</p><p>In the present study, we investigated the role of serum bilirubin on the progression to ESRD in IgA nephropathy. We also analyzed the data in subgroups stratified by well-known risk factors to renal progression in IgA nephropathy and by possible confounding factors affecting serum bilirubin levels, such as gender, age (<xref ref-type="bibr" rid="B16">16</xref>), and serum albumin, to which unconjugated bilirubin is bound (<xref ref-type="bibr" rid="B17">17</xref>).</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Study subjects</title><p>This study was approved by the Institutional Review Board in Seoul National University Bundang Hospital and other participated hospitals before the data were gathered. Informed written consent was obtained from all patients. The subjects were enrolled in the Progressive REnal disease and Medical Informatics and gEnomics Research (PREMIER) program sponsored by the Korean Society of Nephrology (KSN) since August 2003. Thirty-four hospitals and clinics in Korea participated in the PREMIER study and shared the clinical data of 1,469 adult patients aged 18 yr or more who were diagnosed as primary IgA glomerulonephritis by renal biopsy from April 1988 to May 2007. From this group, 1,458 patients whose serum bilirubin data were available were included in this study. We enrolled 30 (2.1%) patients diagnosed before 2000, 41 (2.8%) in 2000, 81 (5.6%) in 2001, 123 (8.4%) in 2002, 170 (11.7%) in 2003, 351 (24.1%) in 2004, 411 (28.2 %) in 2005, 209 (14.3%) in 2006, and 42 (2.9%) in 2007.</p></sec><sec><title>Clinical data</title><p>The participating researchers had selected the candidate patients and one qualified nurse, who visited every participated institution, input the clinical data into the formatted database on the website (<ext-link ext-link-type="uri" xlink:href="http://www.gn.or.kr">http://www.gn.or.kr</ext-link>) at the time of renal biopsy and during follow-up visits. We gathered the data of age, gender, history of diabetes mellitus, and current hypertension, blood pressure, serum protein, serum albumin, serum cholesterol, serum bilirubin, alanine aminotransferase, aspartate aminotransferase, hemoglobin, serum creatinine, proteinuria by dipstick test, urine RBC measured by microscopic examination of urine at renal biopsy, and medication of angiotensin-converting enzyme inhibitors (ACEI), angiotensin II type I receptor blockers (ARB), any kind of steroid and HMG-CoA reductase inhibitor during the follow-up period. Hypertension was defined as a systolic blood pressure (SBP) of 140 mmHg or more, diastolic blood pressure (DBP) of 90 mmHg or more, or the taking of anti-hypertensive medication before renal biopsy. The estimated glomerular filtration rate (eGFR) was calculated by the modified modification of diet in renal disease (MDRD) equation as follow (<xref ref-type="bibr" rid="B18">18</xref>);</p><p>eGFR (mL/min/1.73 m<sup>2</sup>)=186.3&#x000d7;(serum creatinine)<sup>-1.154</sup>&#x000d7;(age)<sup>-0.203</sup> (&#x000d7;0.742 for female)</p><p>We classified the following clinical parameters: age, with the criterion of 35 yr, which was the median value, serum albumin level with 4.0 g/dL, proteinuria by dipstick test with 3+, and hematuria with urine RBC 5 or more in microscopic examination of urine in the field of 400-fold magnification.</p><p>We grouped the patients according to the following quartile levels of serum bilirubin and compared the basal characteristics and ESRD incidence during the follow-up period: &#x0003c;0.4 mg/dL (Q1), 0.4-0.5 mg/dL (Q2), 0.6-0.7 mg/dL (Q3), and &#x0003e;0.8 mg/dL (Q4).</p></sec><sec><title>Renal outcome</title><p>The end point was the time to the first treatment for ESRD. The ESRD data were obtained from the Korean ESRD registry, "Insan Memorial Dialysis Registry", of KSN (<xref ref-type="bibr" rid="B19">19</xref>). The registry contained the data of patients entering into renal replacement therapy (RRT), dialysis or transplantation, in Korea from 1985 to April 2008. The data was reported by providers of RRT on paper documents before 2001 and through an on-line registry program in the KSN website (<ext-link ext-link-type="uri" xlink:href="&#x0003e;http://www.ksn.or.kr">http://www.ksn.or.kr</ext-link>) from 2001. The response rate to collect the data from providers in Korea was 65.1% in 2001 (<xref ref-type="bibr" rid="B19">19</xref>) and 66.8% in 2002 (<xref ref-type="bibr" rid="B20">20</xref>). We searched the data based on the unique personal identifier which all Koreans aged 18 yr or more have and identified the RRT status of patients with IgA nephropathy.</p></sec><sec><title>Statistical analysis</title><p>The SPSS (SPSS version 12.0, Chicago, IL, U.S.A.) package was used for statistical analysis. Differences in proportions among groups were compared by chi-square test. Group differences for continuous variables were assessed by the Student t-test or One-way ANOVA test according to the number of groups. We compared the cumulative incidence of ESRD by Log-rank test. To determine whether the bilirubin level was independently related to the incidence of ESRD, we used the Cox's hazard proportional analysis adjusted for age, gender, and univariate risk factors to the incidence of ESRD. We repeated the analyses after stratification by gender, age and serum albumin, which are the important factors associated with the serum level of bilirubin, and by hypertension, urine protein level and eGFR, which are the well-known prognostic factors of IgA nephropathy. Two-sided <italic>p</italic> values were reported with 0.05 taken as the level of statistical significance. All data are shown as mean&#x000b1;standard deviation or frequency per observation.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>The basal characteristics of patients according to bilirubin levels</title><p>The mean values of age, SBP, serum protein, serum albumin, serum cholesterol, serum creatinine, eGFR, and hemoglobin differed among the bilirubin groups (<xref ref-type="table" rid="T1">Table 1</xref>). The mean values of age, SBP, serum cholesterol and serum creatinine were lower, but those of serum protein, serum albumin, eGFR and hemoglobin were higher, in patients with higher bilirubin level. The frequencies of being female, having proteinuria 3+ or more, having hematuria, and using statin were higher in patients with lower serum bilirubin level.</p></sec><sec><title>The risk factors to the incidence of ESRD in IgA nephropathy</title><p>Eighty of the 1,458 patients (5.5%) contracted ESRD during a mean follow-up period of 44.9 months (SD: 22.3 months). The overall renal survival rate was 98.6% at 1 yr, 93.2% at 5 yr, and 80.7% at 10 yr after renal biopsy. The incidences of ESRD were 10.7% in Q1, 8.2 % in Q2, 2.8% in Q3, and 2.8% in Q4 (<italic>p</italic>&#x0003c;0.001). The mean follow-up period was not different among the bilirubin groups (<italic>p</italic>&#x0003e;0.05). The numbers of patients followed at renal biopsy, at 1, 2, 3, 4, and 5 yr after renal biopsy were 224, 215, 179, 120, 53, and 36 in Q1, 391, 372, 324, 224, 113, and 79 in Q2, 386, 381, 328, 232, 146, and 92 in Q3, and 457, 450, 403, 283, 152, and 93 in Q4, respectively. The probability of ESRD was the highest in Q1 among the bilirubin groups, as shown in <xref ref-type="fig" rid="F1">Fig. 1</xref>.</p><p>The age, SBP, DBP, serum protein, serum albumin, serum bilirubin, hemoglobin, serum creatinine and eGFR, and the frequencies of hypertension, proteinuria 3+ or more, and the usage of steroids were the univariate factors for the incidence of ESRD (<xref ref-type="table" rid="T2">Table 2</xref>). In Cox's hazard proportional model adjusted for gender and univariate risk factors, the bilirubin group was one of the independent risk factors for ESRD (<xref ref-type="table" rid="T3">Table 3</xref>). The relative risk (RR) of ESRD compared to that in Q1 was 0.307 (95% confidence interval [CI], 0.126-0.751) in Q3 and 0.315 (95% CI, 0.130-0.765) in Q4. The other risk factors for ESRD were the presence of hypertension, higher serum creatinine level, and lower serum albumin level at renal biopsy.</p></sec><sec><title>The RR for ESRD among bilirubin groups in subgroups</title><p>We analyzed the RR for ESRD in the bilirubin groups by Cox's hazard proportional model adjusted with univariate risk factors in each subgroup stratified by possible confounding factors to serum bilirubin level and the renal prognosis in IgA nephropathy. In males, the bilirubin group was a risk factor for ESRD and the RR was decreased in Q3 and Q4 compared to that in Q1. Similarly, in patients aged 35 yr or more, with normotension, with serum albumin 4.0 g/dL or more, with eGFR 60 mL/min/1.73 m<sup>2</sup> or more, or with proteinuria less then 3+ by dipstick test, the RR for ESRD in Q3 and Q4 was lower than that in Q1 (<xref ref-type="table" rid="T4">Table 4</xref>).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this study, we observed the incidence of ESRD and the important role of bilirubin level on renal prognosis in a large number of patients with IgA nephropathy in Korea. The overall 10-yr survival rate in IgA nephropathy was reported as about 80% (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>), which was comparable to the rate in this study, although the study population and follow-up duration differed among the various studies. In a U.S.A. paper by Radford et al., the renal survival rate was below the average survival rate because the clinical presentation at renal biopsy was more advanced than in the other studies (<xref ref-type="bibr" rid="B23">23</xref>).</p><p>We collected the data of renal outcome through the Korean ESRD registry. In the database, it was estimated that 65% of the total ESRD patients from institutions undergoing RRT in Korea were registered. Although this registry did not contain 100% of RRT data, we could estimate the effects of bilirubin group on renal survival because the renal survival rate was in agreement with that from other reports and the period of renal biopsy was relatively recent in this study, even though the necessary duration to progress to ESRD in IgA nephropathy is known to be relatively long. In IgA nephropathy, the calculated incidence of ESRD from initial presentation has been reported to be approximately 1.5% per year and about 25 to 30% of published cohorts required RRT within 20 to 25 yr of presentation (<xref ref-type="bibr" rid="B2">2</xref>). In the present study, the frequencies of ESRD according to the diagnosed period were 14.1% before 2001, 12.3% in 2001, 4.1% in 2002, 5.9% in 2003, 6.8% in 2004, 3.4% in 2005, and 2.8% after 2005. These data indicated that the possible error due to incomplete data in estimating renal survival would be less significant in patients with a short duration of disease. Furthermore, if we defined renal progression as a doubling or more of serum creatinine level at follow-up compared to that at renal biopsy, then the RR to renal progression compared to that in Q1 was 0.419 (95% CI, 0.189-0.930) in Q3 and 0.205 (95% CI, 0.075-0.562) in Q4 and the bilirubin group was an independent prognostic factor to renal progression (<italic>p</italic>=0.013 by Cox's hazard progression model adjusted with univariate factors to a doubling or more of serum creatinine) among the 1,031 patients who had repeated serum creatinine values in this study.</p><p>The generally accepted renal prognostic factors in clinical characteristics are age, severity of proteinuria, hypertension, and impaired renal function (reviewed in 2). However, as these factors do not completely account for the risk for ESRD in IgA nephropathy (<xref ref-type="bibr" rid="B2">2</xref>), it is important to define new markers for estimating renal prognosis and for developing a new therapeutic modality in IgA nephropathy. There were few reports on the role of serum bilirubin in chronic renal disease, including glomerulonephritis. In addition to the traditional prognostic factors to renal progression, we revealed that the serum bilirubin level at renal biopsy was an important prognostic factor for ESRD. A serum bilirubin level of 0.6 mg/dL or more (i.e., the bilirubin level in Q3 and Q4) was associated with a lower incidence of ESRD, which is similar to the serum bilirubin level of 10 &#x000b5;M/L used as a cut-off point for the discrimination of cardiovascular risk in other studies (<xref ref-type="bibr" rid="B10">10</xref>).</p><p>Increased oxidative stress was reported to affect the development and progression of IgA nephropathy (<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B6">6</xref>), although glomerular injury in IgA nephropathy is usually provoked by IgA-induced mesangial cell activation and complement activation (<xref ref-type="bibr" rid="B2">2</xref>). Several laboratory investigations have provided a biological background to explain the anti-oxidant and anti-inflammatory effects of bilirubin. Although bilirubin was known to scavenge peroxyl radicals in an in vitro study (<xref ref-type="bibr" rid="B7">7</xref>), the antioxidant effect of bilirubin is usually mediated by inhibition of NADPH oxidase (<xref ref-type="bibr" rid="B8">8</xref>) and protein kinase C activity (9<xref ref-type="bibr" rid="B9">9</xref>). Increased endothelial NADPH oxidase activity is a key mediator of atherosclerosis, including glomerulosclerosis (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>), and activation of NADPH oxidase appears to play a key role in TGF-beta signaling and in the responsiveness of collagen synthesis (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>), which is a common pathway to glomerulosclerosis in various types of glomerulonephritis. The other possibilities to explain the effect of bilirubin on the prognosis of IgA nephropathy are the inverse relationship of bilirubin to insulin resistance, metaolic syndrome (<xref ref-type="bibr" rid="B28">28</xref>) and the atherosclerosis (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). It is well known that the chronic kidney disease including IgA nephropathy is related to insulin resistance and atherosclerosis. The beneficial effect of bilirubin on the prognosis might not be related to the pathogenetic process of IgA nephropathy per se but related to atherosclerosis or insulin resistance which is manifested in IgA nephropathy. But, considering bilirubin was reported to inhibit antigen-specific and polyclonal T cell responses at multiple steps in recent report (<xref ref-type="bibr" rid="B29">29</xref>), bilirubin might also have some roles on the immune regulation in the IgA nephropathy which remains to be verified.</p><p>Although the reason that the relation between bilirubin and renal prognosis in IgA nephropathy was only evident in the male group was not elucidated, the gender effect on the heme oxygenase inducibility to stress, which is the rate-limiting enzyme to produce bilirubin, would be considerable. Trauma and hemorrhage doubled the hepatic HO-1 expression in female rats compared with male rats (<xref ref-type="bibr" rid="B30">30</xref>). The bilirubin effect on renal progression may have been overwhelmed by further severe risk factors such as hypertension, massive proteinuria, or renal impairment, which was in agreement with the finding that the bilirubin group was only a prognostic factor among patients with normotension, with serum albumin 4.0 g/dL or more, with proteinuria less then 3+ by dipstick test, or with eGFR 60 mL/min/1.73 m<sup>2</sup> or more.</p><p>This study suffered several limitations on the generalizability of the results. We had no information on hormonal replacement and the menopausal status, although the mean age of women in this study was younger than the average age of menopause in Korean women, 47 yr, or on fasting status, which affected the level of serum bilirubin. As mentioned above, we could not guarantee 100% of participation rate of RRT providers in gathering information about ESRD and could not estimate the rate of RRT abandonment in newly diagnosed ESRD patients. The data in this study were from many institutions and might have inter-institutional variation according to the devices to measure biological parameters, such as, bilirubin. This limitation may act as a confounding factor to the relation between bilirubin group and renal prognosis.</p><p>Nevertheless, our results have revealed that serum bilirubin level is an important new prognostic factor for renal prognosis in a large cohort of IgA nephropathy. This finding suggests the importance of oxidative stress in renal progression and strengthens the possible therapeutic role of antioxidants in IgA nephropathy.</p></sec><sec><title>APPENDIX</title><p>Members are listed in Appendix.</p><p>Cheju National University Hospital (Eun Hee Jang), Chonbuk National University Medical School (Won Kim), Chonnam National University Medical School (Nam Ho Kim, Woo Kyun Bae), Chungbuk National University College of Medicine (Hye Young Kim), Chungnam National University College of Medicine (Young-Tai Shin, Kang Wook Lee, Ki-Ryang Na), Daegu Catholic University Medical Center (Ki Sung Ahn), Dankook University Hospital (Jong Tae Cho, Eun Kyeong Lee), Dong-A University College of Medicine (Ki Hyun Kim, WonSuk An, Seong Eun Kim), Ewha Womans University School of Medicine (Choi Gyu Bog, Seung-Jung Kim), Gachon University of Medicine and Science (Woo Kyung Chung, Hyun Hee Lee, Jaeseok Yang, Sejoong Kim), Gyeongsang National University Hospital (Se-Ho Chang), Hallym University College of Medicine (Jung Woo Noh, Young Ki Lee, Seong Gyun Kim, Jieun Oh, Young Rim Song), Inha University College of Medicine (Moon Jae Kim, Seoung Woo Lee), Inje University College of Medicine (Yeong Hoon Kim, Won Do Park), Keimyung University School of Medicine (Hyun Chul Kim, Sung Bae Park), Konkuk University School of Medicine (Kyo-Soon Kim), Korea University Anam Hospital (Won Yong Cho, Hyoung Kyu Kim, Sang-Kyung Jo), Korea University Ansan Hospital (Cha Dae Ryong, Kang Young Sun), Korea University College of Medicine Guro Hospital (Young-Joo Kwon), Kyungpook National University School of Medicine (Yong-Lim Kim, Sun-Hee Park, Chan-Duck Kim), Pochon CHA University College of Medicine (Dong Ho Yang), Pusan National University School of Medicine (Ihm Soo Kwak,, Soo Bong Lee, Dong Won Lee, Sang Heon Song, Eun Young Seoung), Seoul Medical Center (Su-Jin Yoon), Seoul National University Bundang Hospital (Dong-Wan Chae, Ki Young Na, Ho Jun Chin), Seoul National University College of Medicine Boramae Medical Center (Chun Soo Lim, Yoon Kyu Oh), Seoul National University Hospital (Kook Hwan Oh, Kwon Wook Joo, Yon-Su Kim, Curie Ahn, Jin Suk Han, Suhnggwon Kim), Seoul National University Hosptial Clinical Institute (Hyung Jin Yoon), Sungkyunkwan University School of Medicine (Kyu-Beck Lee), Sungkyunkwan University School of Medicine Samsung Medical Center (Yoon Goo Kim, Jung Eun Lee), Ulsan University College of Medicine, Asan Medical Center (Sang Koo Lee), Yeungnam University College of Medicine (Jun-Young Do, Jong-Won Park, Kyung-Woo Yoon), ordered by alphabet.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>This study was supported by the <funding-source>Collaborative Research Grant of Korean Society of Nephrology</funding-source>.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donadio</surname><given-names>JV</given-names></name><name><surname>Grande</surname><given-names>JP</given-names></name></person-group><article-title>IgA nephropathy</article-title><source>New Engl J Med</source><year>2002</year><volume>347</volume><fpage>738</fpage><lpage>748</lpage><pub-id pub-id-type="pmid">12213946</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barratt</surname><given-names>J</given-names></name><name><surname>Feehally</surname><given-names>J</given-names></name></person-group><article-title>IgA nephropathy</article-title><source>J Am Soc Nephrol</source><year>2005</year><volume>16</volume><fpage>2088</fpage><lpage>2097</lpage><pub-id pub-id-type="pmid">15930092</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Descamps-Latscha</surname><given-names>B</given-names></name><name><surname>Witko-Sarsat</surname><given-names>V</given-names></name><name><surname>Nguyen-Khoa</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>AT</given-names></name><name><surname>Gausson</surname><given-names>V</given-names></name><name><surname>Mothu</surname><given-names>N</given-names></name><name><surname>Cardoso</surname><given-names>C</given-names></name><name><surname>Noel</surname><given-names>LH</given-names></name><name><surname>Guerin</surname><given-names>AP</given-names></name><name><surname>London</surname><given-names>GM</given-names></name><name><surname>Jungers</surname><given-names>P</given-names></name></person-group><article-title>Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers</article-title><source>Kidney Int</source><year>2004</year><volume>66</volume><fpage>1606</fpage><lpage>1612</lpage><pub-id pub-id-type="pmid">15458457</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobori</surname><given-names>H</given-names></name><name><surname>Katsurada</surname><given-names>A</given-names></name><name><surname>Ozawa</surname><given-names>Y</given-names></name><name><surname>Satou</surname><given-names>R</given-names></name><name><surname>Miyata</surname><given-names>K</given-names></name><name><surname>Hase</surname><given-names>N</given-names></name><name><surname>Suzaki</surname><given-names>Y</given-names></name><name><surname>Shoji</surname><given-names>T</given-names></name></person-group><article-title>Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients</article-title><source>Biochem Biophys Res Commun</source><year>2007</year><volume>358</volume><fpage>156</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">17482564</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>HC</given-names></name><name><surname>Tomino</surname><given-names>Y</given-names></name><name><surname>Yaguchi</surname><given-names>Y</given-names></name><name><surname>Fukui</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>Koide</surname><given-names>H</given-names></name></person-group><article-title>Oxidative metabolism of polymorphonuclear leukocytes (PMN) in patients with IgA nephropathy</article-title><source>J Clin Lab Anal</source><year>1992</year><volume>6</volume><fpage>35</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">1542082</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turi</surname><given-names>S</given-names></name><name><surname>Nemeth</surname><given-names>I</given-names></name><name><surname>Torkos</surname><given-names>A</given-names></name><name><surname>Saghy</surname><given-names>L</given-names></name><name><surname>Varga</surname><given-names>I</given-names></name><name><surname>Matkovics</surname><given-names>B</given-names></name><name><surname>Nagy</surname><given-names>J</given-names></name></person-group><article-title>Oxidative stress and antioxidant defense mechanism in glomerular disease</article-title><source>Free Rad Biol Med</source><year>1997</year><volume>22</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">8958140</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stocker</surname><given-names>R</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>McDonagh</surname><given-names>AF</given-names></name><name><surname>Glazer</surname><given-names>AN</given-names></name><name><surname>Ames</surname><given-names>BN</given-names></name></person-group><article-title>Bilirubin is an antioxidant of possible physiological importance</article-title><source>Science</source><year>1987</year><volume>235</volume><fpage>1043</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">3029864</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanone</surname><given-names>S</given-names></name><name><surname>Bloc</surname><given-names>S</given-names></name><name><surname>Foresti</surname><given-names>R</given-names></name><name><surname>Almolki</surname><given-names>A</given-names></name><name><surname>Taille</surname><given-names>C</given-names></name><name><surname>Callebert</surname><given-names>J</given-names></name><name><surname>Conti</surname><given-names>M</given-names></name><name><surname>Goven</surname><given-names>D</given-names></name><name><surname>Aubier</surname><given-names>M</given-names></name><name><surname>Dureuil</surname><given-names>B</given-names></name><name><surname>El-Benna</surname><given-names>J</given-names></name><name><surname>Motterlini</surname><given-names>R</given-names></name><name><surname>Boczkowski</surname><given-names>J</given-names></name></person-group><article-title>Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats</article-title><source>FASEB J</source><year>2005</year><volume>19</volume><fpage>1890</fpage><lpage>1892</lpage><pub-id pub-id-type="pmid">16129699</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sano</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Matsuo</surname><given-names>T</given-names></name></person-group><article-title>Mode of inhibitory action of bilirubin on protein kinase C</article-title><source>Pediatr Res</source><year>1985</year><volume>19</volume><fpage>587</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">2989761</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novotny</surname><given-names>L</given-names></name><name><surname>Vitek</surname><given-names>L</given-names></name></person-group><article-title>Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies</article-title><source>Exp Biol Med (Maywood)</source><year>2003</year><volume>228</volume><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">12709588</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endler</surname><given-names>G</given-names></name><name><surname>Hamwi</surname><given-names>A</given-names></name><name><surname>Sunder-Plassmann</surname><given-names>R</given-names></name><name><surname>Exner</surname><given-names>M</given-names></name><name><surname>Vukovich</surname><given-names>T</given-names></name><name><surname>Mannhalter</surname><given-names>C</given-names></name><name><surname>Wojta</surname><given-names>J</given-names></name><name><surname>Huber</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>O</given-names></name></person-group><article-title>Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women?</article-title><source>Clin Chem</source><year>2003</year><volume>49</volume><fpage>1201</fpage><lpage>1204</lpage><pub-id pub-id-type="pmid">12816925</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pflueger</surname><given-names>A</given-names></name><name><surname>Croatt</surname><given-names>AJ</given-names></name><name><surname>Peterson</surname><given-names>TE</given-names></name><name><surname>Smith</surname><given-names>LA</given-names></name><name><surname>d'Uscio</surname><given-names>LV</given-names></name><name><surname>Katusic</surname><given-names>ZS</given-names></name><name><surname>Nath</surname><given-names>KA</given-names></name></person-group><article-title>The hyperbilirubinemic Gunn rat is resistant to the pressor effects of angiotensin II</article-title><source>Am J Physiol Renal Physiol</source><year>2005</year><volume>288</volume><fpage>F552</fpage><lpage>F558</lpage><pub-id pub-id-type="pmid">15536166</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adin</surname><given-names>CA</given-names></name><name><surname>Croker</surname><given-names>BP</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name></person-group><article-title>Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney</article-title><source>Am J Phyisol Renal Physiol</source><year>2005</year><volume>288</volume><fpage>F778</fpage><lpage>F784</lpage></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkby</surname><given-names>K</given-names></name><name><surname>Baylis</surname><given-names>C</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Croker</surname><given-names>B</given-names></name><name><surname>Archer</surname><given-names>L</given-names></name><name><surname>Adin</surname><given-names>C</given-names></name></person-group><article-title>Intravenous bilirubin provides incomplete protection against renal ischemia-reperfusion injury in vivo</article-title><source>Am J Physiol Renal Physiol</source><year>2007</year><volume>292</volume><fpage>F888</fpage><lpage>F894</lpage><pub-id pub-id-type="pmid">17032942</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakao</surname><given-names>A</given-names></name><name><surname>Neto</surname><given-names>JS</given-names></name><name><surname>Kanno</surname><given-names>S</given-names></name><name><surname>Stolz</surname><given-names>DB</given-names></name><name><surname>Kimizuka</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Bach</surname><given-names>FH</given-names></name><name><surname>Billiar</surname><given-names>TR</given-names></name><name><surname>Choi</surname><given-names>AM</given-names></name><name><surname>Otterbein</surname><given-names>LE</given-names></name><name><surname>Murase</surname><given-names>N</given-names></name></person-group><article-title>Protection against ischemia/reperfusion injury in cardiac and renal transplantation with carbon monoxide, biliverdin and both</article-title><source>Am J Transplant</source><year>2005</year><volume>5</volume><fpage>282</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">15643987</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manolio</surname><given-names>TE</given-names></name><name><surname>Burke</surname><given-names>GL</given-names></name><name><surname>Savage</surname><given-names>PJ</given-names></name><name><surname>Jacobs</surname><given-names>DR</given-names><suffix>Jr</suffix></name><name><surname>Sidney</surname><given-names>S</given-names></name><name><surname>Wagenknecht</surname><given-names>LE</given-names></name><name><surname>Allman</surname><given-names>RM</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name></person-group><article-title>Sex- and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study</article-title><source>Clin Chem</source><year>1992</year><volume>38</volume><fpage>1853</fpage><lpage>1859</lpage><pub-id pub-id-type="pmid">1526025</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>R</given-names></name><name><surname>Diamond</surname><given-names>I</given-names></name><name><surname>Hammaker</surname><given-names>L</given-names></name><name><surname>Gundersen</surname><given-names>CB</given-names></name></person-group><article-title>Interaction of bilirubin with albumin</article-title><source>Nature</source><year>1965</year><volume>206</volume><fpage>1041</fpage><lpage>1043</lpage><pub-id pub-id-type="pmid">5839057</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Eckardt</surname><given-names>KU</given-names></name><name><surname>Tsukamoto</surname><given-names>Y</given-names></name><name><surname>Levin</surname><given-names>A</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Rossert</surname><given-names>J</given-names></name><name><surname>De Zeeuw</surname><given-names>D</given-names></name><name><surname>Hostetter</surname><given-names>TH</given-names></name><name><surname>Lameire</surname><given-names>N</given-names></name><name><surname>Eknoyan</surname><given-names>G</given-names></name></person-group><article-title>Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)</article-title><source>Kidney Int</source><year>2005</year><volume>67</volume><fpage>2089</fpage><lpage>2100</lpage><pub-id pub-id-type="pmid">15882252</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Jin</surname><given-names>DC</given-names></name><name><surname>Bang</surname><given-names>BK</given-names></name></person-group><article-title>Current status of dialytic therapy in Korea</article-title><source>Nephrology (Carlton)</source><year>2003</year><volume>8</volume><issue>Suppl</issue><fpage>S2</fpage><lpage>S9</lpage><pub-id pub-id-type="pmid">15012684</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>GH</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name></person-group><article-title>Comparison of anthropometric data between end-stage renal disease patients undergoing hemodialysis and healthy adults in Korea</article-title><source>Yonsei Med J</source><year>2005</year><volume>46</volume><fpage>658</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">16259064</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moranne</surname><given-names>O</given-names></name><name><surname>Watier</surname><given-names>L</given-names></name><name><surname>Rossert</surname><given-names>J</given-names></name><name><surname>Stengel</surname><given-names>B</given-names></name></person-group><collab>GN-Progress Study Group</collab><article-title>Primary glomerulonephritis: an update on renal survival and determinants of progression</article-title><source>QJM</source><year>2008</year><volume>101</volume><fpage>215</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">18245806</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibels</surname><given-names>LS</given-names></name><name><surname>Gyory</surname><given-names>AZ</given-names></name></person-group><article-title>IgA nephropathy: analysis of the natural history, important factors in the progression of renal disease, and a review of the literature</article-title><source>Medicine (Baltimore)</source><year>1994</year><volume>73</volume><fpage>79</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">8152367</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radford</surname><given-names>MG</given-names></name><name><surname>Donadio</surname><given-names>JV</given-names></name><name><surname>Bergstralh</surname><given-names>EJ</given-names></name><name><surname>Grande</surname><given-names>JP</given-names></name></person-group><article-title>Predicting renal outcome in IgA nephropathy</article-title><source>J Am Soc Nephrol</source><year>1997</year><volume>8</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">9048338</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>JM</given-names></name><name><surname>Shah</surname><given-names>AM</given-names></name></person-group><article-title>ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy</article-title><source>J Am Soc Nephrol</source><year>2003</year><volume>14</volume><issue>8 Suppl 3</issue><fpage>S221</fpage><lpage>S226</lpage><pub-id pub-id-type="pmid">12874435</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitada</surname><given-names>M</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Sugimoto</surname><given-names>T</given-names></name><name><surname>Isono</surname><given-names>M</given-names></name><name><surname>Araki</surname><given-names>S</given-names></name><name><surname>Kashiwagi</surname><given-names>A</given-names></name><name><surname>Haneda</surname><given-names>M</given-names></name></person-group><article-title>Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>2603</fpage><lpage>2614</lpage><pub-id pub-id-type="pmid">14514646</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thannickal</surname><given-names>VJ</given-names></name><name><surname>Fanburg</surname><given-names>BL</given-names></name></person-group><article-title>Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1</article-title><source>J Biol Chem</source><year>1995</year><volume>270</volume><fpage>30334</fpage><lpage>30338</lpage><pub-id pub-id-type="pmid">8530457</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Cook</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Valancius</surname><given-names>C</given-names></name><name><surname>Inscho</surname><given-names>EW</given-names></name></person-group><article-title>TGF-beta impairs renal autoregulation via generation of ROS</article-title><source>Am J Physiol Renal Physiol</source><year>2005</year><volume>288</volume><fpage>F1069</fpage><lpage>F1077</lpage><pub-id pub-id-type="pmid">15644487</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>LY</given-names></name><name><surname>Kuo</surname><given-names>HK</given-names></name><name><surname>Hwang</surname><given-names>JJ</given-names></name><name><surname>Lai</surname><given-names>LP</given-names></name><name><surname>Chiang</surname><given-names>FT</given-names></name><name><surname>Tseng</surname><given-names>CD</given-names></name><name><surname>Lin</surname><given-names>JL</given-names></name></person-group><article-title>Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents</article-title><source>Atherosclerosis</source><year>2008</year><month>7</month><day>26</day><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Oger</surname><given-names>J</given-names></name><name><surname>Tetzlaff</surname><given-names>W</given-names></name><name><surname>Cynader</surname><given-names>M</given-names></name></person-group><article-title>Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis</article-title><source>J Immunol</source><year>2008</year><volume>181</volume><fpage>1887</fpage><lpage>1897</lpage><pub-id pub-id-type="pmid">18641326</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toth</surname><given-names>B</given-names></name><name><surname>Yokoyama</surname><given-names>Y</given-names></name><name><surname>Kuebler</surname><given-names>JF</given-names></name><name><surname>Schwacha</surname><given-names>MG</given-names></name><name><surname>Rue</surname><given-names>LW</given-names><suffix>3rd</suffix></name><name><surname>Bland</surname><given-names>KI</given-names></name><name><surname>Chaudry</surname><given-names>IH</given-names></name></person-group><article-title>Sex differences in hepatic heme oxygenase expression and activity following trauma and hemorrhagic shock</article-title><source>Arch Surg</source><year>2003</year><volume>138</volume><fpage>1375</fpage><lpage>1382</lpage><pub-id pub-id-type="pmid">14662543</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>The probability of renal survival according to serum bilirubin level at renal biopsy.</p><p>Q1, First quartile group; Q2, Second quartile group; Q3, Third quartile group; Q4, Forth quartile group.</p></caption><graphic xlink:href="jkms-24-S22-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>The characteristics of patients at renal biopsy</p></caption><graphic xlink:href="jkms-24-S22-i001"/><table-wrap-foot><fn><p><sup>*</sup>, Difference of frequency compared to Q1 bilirubin group, <italic>p</italic>&#x0003c;0.05, number/number: mean/standard deviation.</p><p>Number right upper side of data: Duncan post hoc analysis in One-Way ANOVA test.</p><p>DM, diabetes mellitus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; proteinuria &#x02265;3+, proteinuria 3+ or more by dipstick test; hematuria, urine RBC 5 or more by microscopic examination of urine in a filed of 400-fold magnification; ACEI or ARB, angiotensin converting enzyme inhibitor or angiotensin II type I receptor blocker; Statin, HMG-Co reductase inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>The difference of basal characteristics according to renal progression to end-stage renal disease (ESRD)</p></caption><graphic xlink:href="jkms-24-S22-i002"/><table-wrap-foot><fn><p>Number/number, mean/standard deviation.</p><p>DM, diabetes mellitus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; proteinuria &#x02265;3+, proteinuria 3+ or more by dipstick test; hematuria, urine RBC 5 or more by microscopic examination of urine in a filed of 400-fold magnification; ACEI or ARB, angiotensin converting enzyme inhibitor or angiotensin II type I receptor blocker; Statin, HMG-Co reductase inhibitor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>The independent risk factor to the incidence of end-stage renal disease in IgA nephropathy analyzed by Cox's hazard proportional model</p></caption><graphic xlink:href="jkms-24-S22-i003"/><table-wrap-foot><fn><p>Adjusted with age, gender, hypertension, systolic blood pressure, diastolic blood pressure, serum albumin, serum creatinine, urine protein 3+ or more by dipstick test, and bilirubin groups.</p><p><sup>*</sup>Compared to bilirubin group, first quartile group with bilirubin less than 0.4 mg/dL.</p><p>OR, odds ratio; C.I., confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>The relative risk to ESRD in patients with IgA nephropathy after stratification with clinical parameters analyzed by Cox's hazard proportional model</p></caption><graphic xlink:href="jkms-24-S22-i004"/><table-wrap-foot><fn><p><sup>*</sup>: Compared to bilirubin group, first quartile group with bilirubin less than 0.4 mg/dL, ref.: reference group; <sup>&#x02020;</sup>: Model adjusted with age, hypertension, SBP, serum albumin, serum creatinine, proteinuria 3+ or more, and bilirubin groups which were univariate factors to ESRD in this subgroup; <sup>&#x02021;</sup>: Model adjusted with gender, hypertension, SBP, DBP, serum albumin, serum creatinine, and bilirubin groups which were univariate factors to ESRD in this subgroup; <sup>&#x000a7;</sup>: Model adjusted with age, serum albumin, serum creatinine, proteinuria 3+ or more, and bilirubin groups which were univariate factors to ESRD in this subgroup; <sup>&#x02225;</sup>: Model adjusted with serum albumin, serum creatinine, and bilirubin groups which were univariate factors to ESRD in this subgroup; <sup>&#x000b6;</sup>: Model adjusted with gender, age, and bilirubin groups which were univariate factors to ESRD in this subgroup, <sup>**</sup>: Model adjusted with diabetes mellitus, hypertension, SBP, DBP, serum albumin, serum creatinine, and bilirubin groups which were univariate factors to ESRD in this subgroup.</p></fn></table-wrap-foot></table-wrap></floats-group></article>